Algene, Genset deal

AGN.B will exclusively license to GENSET Alzheimer's disease (AD) DNA collections and gene mapping results that AGN.B has compiled from a phenotyped collection of samples from AD patients within the Quebec founder population. AGN.B has identified several chromosomal regions that may contain genes associated with AD. GENSET will use its genomics technologies to generate biallelic markers in these regions, perform high throughput genotyping of the sample collection and apply its bioinformatics tools to analyze resulting association data. ...